Inverse 1,2,3-triazole-1-yl-ethyl substituted hydroxamates as highly potent matrix metalloproteinase inhibitors: (Radio)synthesis, in vitro and first in vivo evaluation

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6858-6870

  Hugenberg, Verena ^a   Riemann, Burkhard ^a   Hermann, Sven ^b   Schober, Otmar ^a   Schäfers, Michael ^b,c   Szardenings, Katrin ^d   Lebedev, Artem ^d   Gangadharmath, Umesh ^d   Kolb, Hartmuth ^d   Walsh, Joseph ^d   Zhang, Wei ^d   Kopka, Klaus ^a,e   Wagner, Stefan ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Building D3   (Germany)

^d SIEMENS CORPORATE RESEARCH   (United States)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [N [2 [4 (3 FLUOROPROPYL) 1H 1,2,3 TRIAZOL 1 YL]ETHYL] 4 METHOXYPHENYLSULFONAMIDO] N HYDROXY 3 METHYLBUTANAMIDE F 18; HYDROXAMIC ACID DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; IC 50; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HYDROXAMIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; PROTEASE INHIBITORS; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84884248169     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4006753     Document Type: Article

References (47)

1. Matrix Metalloproteinases and TIMPs; Woessner, J. F.; Nagase, H., Eds.; Oxford University Press: New York, 2000
2. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Chem. Rev. 1999, 99, 2735-2776
3. Fingleton, B. Matrix metalloproteinases: roles in cancer and metastasis Front. Biosci. 2006, 11, 479-491
4. Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment Cell 2010, 141, 52-67
5. Gialeli, C.; Theocharis, A. D.; Karamanos, N. K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting FEBS J. 2011, 278, 16-27
6. Galis, Z. S.; Khatri, J. J. Matrix metalloproteinases in vascular remodeling and antherogenesis: The good, the bad, and the ugly Circ. Res. 2002, 90, 251-262
7. George, S. J. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis Expert Opin. Invest. Drugs 2000, 9, 993-1007
8. Okamoto, H.; Hoshi, D.; Kiire, A.; Yamanaka, H.; Kamatani, N. Molecular targets of rheumatoid arthritis Inflamm. Allergy Drug Targets 2008, 7, 53-66
9. Troeberg, L.; Nagase, H. Proteases involved in cartilage matrix degradation in osteoarthritis Biochim. Biophys. Acta 2012, 1824, 133-145
10. Honibald, E. N.; Mathew, S.; Padmanaban, J.; Sundaram, E.; Ramamoorthy, R. D. Perioceutics: Matrix metalloproteinase inhibitors as an adjunctive therapy for inflammatory periodontal disease J. Pharm. Bioallied Sci. 2012, 4 (Suppl 2) 417-421
11. Muroski, M. E.; Roycik, M. D.; Newcomer, R. G.; Van den Steen, P. E.; Opdenakker, G.; Monroe, H. R.; Sahab, Z. J.; Sang, Q. X. Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis Curr. Pharm. Biotechnol. 2008, 9, 34-46
12. Brauer, P. R. MMPs-role in cardiovascular development and disease Front. Biosci. 2006, 11, 447-478
13. Papazafiropoulou, A.; Tentolouris, N. Matrix metalloproteinases and cardiovascular diseases Hippokratia 2009, 13, 76-82
14. Fisher, J. F.; Mobashery, S. Recent advances in MMP inhibitor design Cancer Metastasis Rev. 2006, 25, 115-136
15. Corbitt, C. A.; Lin, J.; Lindsey, M. L. Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat. Anti-Cancer Drug Discovery 2007, 2, 135-142
16. Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition Biochim. Biophys. Acta, Mol. Cell Res. 2010, 1803, 72-94
17. Verma, R. P.; Hansch, C. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs Bioorg. Med. Chem. 2007, 15, 2223-2268
18. Skiles, J. W.; Gonnella, N. C.; Jeng, A. Y. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors Curr. Med. Chem. 2004, 11, 2911-2977
19. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S. I.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; ÓByrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits J. Med. Chem. 1997, 40, 2525-2532
20. Scozzafava, A.; Supuran, C. T. Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N -hydroxysulfonamides inhibit both these zinc enzymes J. Med. Chem. 2000, 43, 3677-3687
21. Faust, A.; Waschkau, B.; Waldeck, J.; Höltke, C.; Breyholz, H.-J.; Wagner, S.; Kopka, K.; Schober, O.; Heindel, W.; Schäfers, M.; Bremer, C. Synthesis and evaluation of a novel hydroxamate based fluorescent photoprobe for imaging matrix metalloproteinases Bioconjugate Chem. 2009, 20, 904-912
22. Waschkau, B.; Faust, A.; Schäfers, M.; Bremer, C. Performance of a new fluorescence-labeled MMP inhibitor to image tumor MMP activity in vivo in comparison to an MMP-activatable probe Contrast Media Mol. Imaging 2013, 8, 1-11
23. Kopka, K.; Breyholz, H.-J.; Wagner, S.; Law, M. P.; Riemann, B.; Schröer, S.; Trub, M.; Guilbert, B.; Levkau, B.; Schober, O.; Schäfers, M. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo Nucl. Med. Biol. 2004, 31, 257-267
24. Schäfers, M.; Riemann, B.; Kopka, K.; Breyholz, H.-J.; Wagner, S.; Schäfers, K. P.; Law, M.P.; Schober, O.; Levkau, B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo Circulation 2004, 109, 2554-2559
25. 18F-radiolabelled analogue of CGS 27023A for assessment of matrix-metalloproteinase activity in vivo Q. J. Nucl. Med. Mol. Imaging 2007, 51, 24-32
26. Wagner, S.; Breyholz, H.-J.; Law, M. P.; Faust, A.; Höltke, C.; Schröer, S.; Haufe, G.; Levkau, B.; Schober, O.; Schäfers, M.; Kopka, K. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N -hydroxy-2(R)-{[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino}-3- methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET J. Med. Chem. 2007, 50, 5752-5764
27. 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies Appl. Radiat. Isot. 2009, 67, 606-610
28. Schäfers, M.; Schober, O.; Hermann, S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques J. Nucl. Med. 2010, 51, 663-666
29. 18F]fluoroethoxy) phenylsulfonamido)- N -hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis Appl. Radiat. Isot. 2011, 69, 862-868
30. Falcinelli, E.; Pompili, M.; Pengo, V.; Appolloni, V.; Guglielmini, G.; Gresele, P. Higher levels of plasma matrix metalloproteinase-2 are associated with a significantly increased risk of arterial thrombosis in patients with the antiphospholipid syndrome Int. J. Cardiol. 2012, 160, 149-151
31. Pussinen, P. J.; Sarna, S.; Puolakkainen, M.; Ohlin, H.; Sorsa, T.; Pesonen, E. The balance of serum matrix metalloproteinase-8 and its tissue inhibitor in acute coronary syndrome and its recurrence Int. J. Cardiol. 2013, 167, 362-268
32. Halade, G. V.; Jin, Y. F.; Lindsey, M. L. Matrix metalloproteinase (MMP)-9: A proximal biomarker for cardiac remodeling and a distal biomarker for inflammation Pharmacol. Ther. 2013, 139, 32-40
33. Suzuki, H.; Kusuyama, T.; Sato, R.; Yokota, Y.; Tsunoda, F.; Sato, T.; Shoji, M.; Iso, Y.; Koba, S.; Katagiri, T. Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction Eur. J. Clin. Invest. 2008, 38, 166-173
34. Yun, L.; Ai-Zhong, S.; Hai-Tao, J.; Guo-Hua, D.; Biao, X.; Jun, Y.; Hua, J. The Prominent Expression of Plasma Matrix Metalloproteinase-8 in Acute Thoracic Aortic Dissection J. Surg. Res. 2010, 163, e99-e104
35. Pirard, B.; Matter, H. Matrix metalloproteinase target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis J. Med. Chem. 2006, 49, 51-69
36. Hugenberg, V.; Breyholz, H.-J.; Riemann, B.; Hermann, S.; Schober, O.; Schäfers, M.; Gangadharmath, U.; Mocharla, V.; Kolb, H.; Walsh, J.; Zhang, W.; Kopka, K.; Wagner, S. A new class of highly potent matrix metalloproteinase inhibitors based on triazole-substituted hydroxamates: (radio)synthesis and in vitro and first in vivo evaluation J. Med. Chem. 2012, 55, 4714-4727
37. Macleod, F.; Lang, S.; Murphy, J. A. The 2-(2-Azidoethyl)cycloalkanone strategy for bridged amides and medium-sized amine derivatives in the Aubé-Schmidt reaction Synlett 2010, 529-534
38. 18F] fluoroethylazide for positron emission tomography Bioconjugate Chem. 2007, 18, 989-993
39. Breyholz, H.-J.; Wagner, S.; Faust, A.; Riemann, B.; Höltke, C.; Hermann, S.; Schober, O.; Schäfers, M.; Kopka, K. Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging ChemMedChem 2010, 5, 777-789
40. Schrigten, D.; Breyholz, H.-J.; Wagner, S.; Hermann, S.; Schober, O.; Schäfers, M.; Haufe, G.; Kopka, K. A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-targeted Radiotracers for Positron Emission Tomography J. Med. Chem. 2012, 55, 223-232
41. Huang, W.; Meng, Q.; Suzuki, K.; Nagase, H.; Brew, K. Mutational study of the amino-terminal domain and human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metallo proteinases J. Biol. Chem. 1997, 272, 22086-22091
42. Gupta, S. P.; Patil, V. M. EXS 2012, 103, 35-56
43. Jin, Y.; Roycik, M. D.; Bosco, D. B.; Cao, Q.; Constantino, M. H.; Schwartz, M. A.; Sang, Q-X. A. Matrix Metalloproteinase Inhibitors Based on the 3-Mercaptopyrrolidine Core J. Med. Chem. 2013, 56, 4357-4373
44. Michel, K.; Büther, K.; Law, M. P.; Wagner, S.; Schober, O.; Hermann, S.; Schäfers, M.; Riemann, B.; Höltke, C.; Kopka, K. Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography J. Med. Chem. 2011, 54, 939-948
45. Ramenda, T.; Kniess, T.; Bergmann, R.; Steinbach, J.; Wuest, F. Radiolabelling of proteins with fluorine-18 via click chemistry Chem.Commun. 2009, 48, 7521-7523
46. Prante, O.; Hocke, C.; Löber, S.; Hübner, H.; Gmeiner, P.; Kuwert, T. Tissue distribution of radioiodinated FAUC113: assessment of a pyrazolo[1,5- a ]pyridine-based dopamine D4 receptor radioligand candidate Nuklearmedizin 2006, 45, 41-48
47. Schäfers, K. P.; Reader, A. J.; Kriens, M.; Knoess, C.; Schober, O.; Schäfers, M. Performance Evaluation of the 32-module quadHIDAC small animal PET scanner J. Nucl. Med. 2005, 46 (6) 996-1004